<DOC>
	<DOC>NCT00635089</DOC>
	<brief_summary>This study is an open-label study where all subjects will receive active drug, reslizumab. Subjects are able to enter this trial only through completion of study Res-05-0002 (NCT00538434). The goal of the study is to show longer term safety and efficacy in pediatric subjects who have eosinophilic esophagitis.</brief_summary>
	<brief_title>Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis</brief_title>
	<detailed_description>Subjects will enter this open-label extension study after completing the placebo-controlled, double-blind study Res-5-0002 (NCT00538434). The end of study visit for Res-05-0002 will serve as the screening visit for this trial. All subjects will receive reslizumab and be followed by their principal investigators in an unblinded fashion. Visits and administration of reslizumab will be monthly.</detailed_description>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<criteria>Informed consent Received at least two doses of study drug in Study Res050002 (NCT00538434) Did not withdraw from Study Res050002 due to drug related adverse event Completed End of Treatment Visit for Study Res050002 Pregnant or nursing females Concurrent Immunodeficiency Current use of immunosuppressive drugs Did not tolerate study drug in Study Res050002</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Eosinophilic Esophagitis</keyword>
	<keyword>Cinquil</keyword>
</DOC>